Absorption Correction Method for
Simultaneous Estimation of Nifedipine and Metoprolol Succinate in Their
Synthetic Mixture Using From Spectrophotometry
Sojitra Rajanit*,
ViraniParas, Hashumati Raj
Department of Quality
Assurance, Shree Dhanvantry Pharmacy College, Kim, Surat.
*Corresponding Author E-mail: rajanit.sojitra@gmail.com
ABSTRACT:
A new simple, economical, precise and accurate method are described
for the simultaneous determination of Nifedipine
(NIF) and Metoprolol Succinate
(MET) in combined tablet dosage form. The proposed method was applied for the
determination of Nifedipine and Metoprolol
Succinate in synthetic mixture, for determination of
sampling wavelength, 10μg/ml of each of NIF and MET were scanned in
200-400 nm range and sampling wavelengths were 313nm for NIF and 275.40nm for
MET are selected for development and validation of absorption correction
method. For this method linearity observed in the range of 5-25μg/ml
for NIF and 25-125μg/ml for MET, and in their pharmaceutical formulation
with mean percentage recoveries 100.68 and 100.33, respectively. The
method was validated according to ICH guidelines and can be applied for routine
quality control testing.
KEY
WORDS: Spectroscopic method, absorption correctedmethod,
Nifedipine and Metoprolol Succinate.
1. INTRODUCTION:
The aim of the present work was to develop a new
simple, rapid, selective method for the simultaneous determination of
components having overlapping spectra in binary mixtures, having the advantages
of minimal data processing and a wider range of applications over the
previously mentioned methods. To prove the ability of the newly described
method in resolving the overlapping spectral data and simultaneous
determination of each component, it was applied for the analysis of a mixture
of Nifedipine (NIF) and Metoprolol
Succinate (MET) formulated together in the form of
synthetic mixture widely used for the treatment of heart related problems accompanying
several hypertension.
Nifedipine is dimethyl 1,
4-dihydro-2, 6- dimethyl-4-(2-nitrophenyl)pyridine-3,5- dicarboxylate.1,2
It is a calcium channel blocker, one of the most widely used coronary
vasodilators.3,4 Nifedipine acts by
blocking the inward movement of calcium by binding to L-type calcium channels
in the heart and smooth muscle of the coronary and peripheral arteriolar
vasculature. This causes vascular smooth muscle to relax, dilating mainly
arterioles.5,6
Metoprolol succinate is a selective
β-adrenergic antagonist, which is used in the treatment of cardiovascular
disorders such as hypertension, angina pectoris, cardiac arrhythmias,
congestive heart failure and myocardial infarction. Metoprolol
is administered orally as tablet. Chemically Metoprolol
succinate is (RS)-1- (Isopropylamino)-3-[p-(2-methoxyethyl)
phenoxy] propan-2- ol succinate with molecular formula C34H54N2O10.7,8
(A)
(B)
Fig.1 (A) is
Structure of Nifedipine and (B) is structure of Metoprolol Succinate.
1.1. THEORY
·
This
method is modification of simultaneous equation method. This method uses the absorbances at two selected wavelengths, one at λmax of one drug where other drug also shows
considerable absorbance (λ2) and other being the wavelength at which the
first drug has practically nil absorbance (λ1).
·
The
concentration of two drugs (X and Y) in sample solution was calculated by using
following equations:
Cy = A2 / ay2……………………………. (1)
Cx = A1-ay1* Cy/ax1....................
..........(2)
Where, A1 and A2 are
the absorbances of mixture at λ1 and λ2
respectively, ay1 and ay2 are absorptivities of y at
λ1 and λ2 respectively, ax1 is absorptivity
of X at λ2, CX is concentration of X, CY is concentration of Y.
2. MATERIAL AND METHOD:
2.1.
Apparatus
A double beam UV/Visible spectrophotometer
(Shimadzu
model2450, Japan) with spectral
width of 2nm, 1 cm quartz cells
was used to measure absorbance
of all the solutions. Spectra
were automatically
obtained by UV-Probe system software.
2.2.
Reference samples
NIF and MET reference standard are kindly
supply by J.B. Chemicals, Ankleshwar and CTX Life
Science, Surat as a gift sample respectively.
2.3.
MATERIALS AND REAGENTS
Methanol AR grade (RANKEM)
2.4. STANDARD SOLUTIONS
Accurately weighed
quantity of
NIF 10mg was transferred to 100ml volumetric
flask, dissolved
and diluted upto mark with Methanol to give a stock solution
having
strength 100µg/ml.
Accurately weighed quantity
of MET 50mg was transferred
into100ml volumetric
flask,
dissolved and diluted
up to mark with Methanol to give a stock
solution having
strength 500µg/ml.
Pipette out accurately 0.5ml
of NIF stock solution (100µg/ml), 0.5ml of MET stock solution (500µg/ml)
in 10 ml volumetric flask and make up the volume up to the mark with Methanol.
It gives solution containing NIF 5µg/ml, MET 25µg/ml.
Dissolve synthetic mixture formulation in 100ml volumetric
flask containing 100ml methanol. Take 1ml mixture sample solution in 10ml
volumetric flask and make up volume up to mark with methanol.
2.5. PROCEDURES
2.5.1. Construction of
calibration curves (linearity)
This series consisted
of five concentrations
of standard NIF solution ranging
from 5-25μg/ml.
The solutions were prepared
by pipetting out standard NIF stock solution
(0.5ml, 1ml, 1.5ml, 2.0ml, 2.5ml)
was transferred
into a series of 10ml volumetric flasks
and volume was adjusted upto mark with Methanol. A zero
order
spectra of the resulting
solutions were recorded,
measured
the absorbance at
313nm against are agent
blank
solution (Methanol). Calibration curve
was
prepared by
plotting absorbance versus respective
concentration of NIF.
This series consisted
of five concentrations of standard MET solution ranging from
25-125μg/ml. The solutions were prepared by
pipetting
out Standard MET stock solution
(0.5ml, 1ml, 1.5ml, 2.0ml, 2.5ml)was transferred
into a seriesof10ml volumetric flasks
and volume was adjusted upto mark with Methanol. A zero
order
spectra of the resulting
solutions were recorded and
measured
the absorbance at
275.40nm against are agent
blank
solution (Methanol). Calibration curve
was
prepared by
plotting absorbance versus respective
concentration of MET.
FIG.
2 Overlain linear zero
order spectra
of NIF (Red) and MET(Blue)
in1:5 ratio
2.5.2. Analysis of
laboratory-prepared mixtures.
Laboratory-prepared mixtures containing different ratios of
NIF and MET were prepared. By applying the procedure under linearity, absorbances at 313nm were recorded for NIF and 275.40nm
were recorded for MET. The concentration of each drug in each mixture was
calculated from its corresponding Cx and Cy equation. Validity of the method was assessed by spiking
the pharmaceutical formulation by known amounts of standard drug powders
(standard addition technique). The recovery of the added standards was then
calculated after applying the proposed method.
2.5.3. Application of the
proposed method for the simultaneous determination of NIF and MET in synthetic
mixture.
Ř
In
that mixture the excipient were like HPMC, silicon
dioxide and guar gum were taken as per the required weight. With the Nifedipine and Metoprolol Succinate with the ratio dissolved in methanol with all excipient.
Ř
Finally
the in the Synthetic mixture had the concentration 100µg/ml
and 500µg/ml respectively for NIF and MET. After that
from this solution 1ml was pipette out and diluted upto
10ml with methanol. So the concentration was 10 µg/ml
and 50 µg/ml for NIF and MET respectively.
3.
RESULTS AND DISCUSSION:
The absorbance wavelength for
NIF and MET found to be 313nm and 275.40nm, respectively, which are different
and hence non-overlapping. Thus simultaneous determination of NIF and MET in
bulk mixture-I and synthetic mixture solution-I was found to be successful by absorption
corrected.
3.1.Specificity
The specificity of the method
was investigated by observing any interference of one drug with other two drugs
in bulk mixture and formulation solution. Similarly the interference of excipients of synthetic mixture with drugs was
investigated.
3.2. Linearity and Range
The linearity of method is its
ability within a given range to obtain test results which are directly or
through a mathematical transformation, proportional to the concentration of analyte. Linearity of the method was determined at five
concentration levels for NIF and MET independently.
3.3.Accuracy
The accuracy of an analytical
method is the closeness of the test results to the true value. It was tested by
spiking standard NIF solution in different concentration 80, 100 and 120% to a
tablet solution. The synthetic mixture solution was analyzed at 313nm for
estimation of NIF. Similarly, the accuracy for MET was determined at 275.40nm,
respectively.
3.4.Precision
The intra-day precision
(repeatability) of method was determined by measuring the absorbance of
synthetic mixture solution-I at 313nm and 275.40nm for NIF and MET,
respectively. Within a laboratory over a short period of
time. The inter-day precision (intermediate precision) was determined by
measuring the absorbance of synthetic mixture solution-I at 313nm and 275.40nm
for NIF and MET, respectively. Within a laboratory on three
consecutive days, by different analysts. The %RSD was calculated for
intra and inter-day precision.
3.5. LOD and LOQ
The LOD of an analytical
method is the lowest amount of analyte in a sample
which can be detected but not necessarily quantified. The detection limit (DL)
of method was determined by equation, DL = (3.3 σ)/S, where, σ–
standard deviation of blank response, S– slope of the calibration curve. The quantitation limit (QL) of analyte
was determined by equation DL = (10 σ)/S, where, σ– standard
deviation of blank response, S– slope of the calibration curve
3.6. Robustness and Ruggedness
Robustness and ruggedness of
the method has been evaluated at two different levels i.e. change in stock
solution and changing the instrument.
4. ANALYSIS OF SYNTHETIC MIXTURE:
The proposed method was
successfully applied to the analysis of both mixtures in their pharmaceutical
preparations. Results obtained were precise and in good agreement with the labelled claim as concluded from the satisfactory values of
% recovery and RSD (%) gathered in table 2 and 3. Proposed method is precise
and accurate, and give same result in same day and between the day and this
data is gathered in table 1. When we change in standard stock concentration or
changed the instrument that time also this proposed method give good result
this data also gathered in table 4 and 5.
Table 1
Interday and intraday precision data for Nifedipine
and Metoprolol Succinate in
three different concentration ranges.
|
PRECISION |
Conc.μg/ml |
Nifedipine |
Conc. μg/ml |
Metoprolol Succinate |
|
313nm |
275.40nm |
|||
|
INTRADAY (n=3)Abs.±%RSD |
5 |
0.038± 0.64 |
25 |
0.157± 0.65 |
|
10 |
0.117± 0.54 |
50 |
0.272± 0.49 |
|
|
|
15 |
0.191± 0.46 |
75 |
0.386± 0.40 |
|
INTERDAY (n=3)Abs.±%RSD |
5 |
0.040± 0.71 |
25 |
0.160± 0.75 |
|
10 |
0.118± 0.60 |
50 |
0.172± 0.54 |
|
|
|
15 |
0.192± 0.40 |
75 |
0.388± 0.22 |
Table 2
Accuracy data for Nifedipineand Metoprolol
Succinate with % recovery and % RSD
|
Level of recovery |
Initial conc. (µg/ml) |
Quantity
of Std. Added(µg/ml) |
Total Amount (µg/ml) |
Result of recovery study |
||||||||||||||||
|
Total Quantity
Found* (µg/ml) ± %RSD |
%Recovery ± %RSD |
|||||||||||||||||||
|
LEVEL |
NIF |
MET |
NIF |
MET |
NIF |
MET |
NIF |
MET |
NIF |
MET |
||||||||||
|
Placebo |
10 |
50 |
- |
- |
10 |
50 |
10.05± 0.26 |
50.15± 0.30 |
100.50 ± 0.30 |
100.30 ± 0.25 |
||||||||||
|
80% |
10 |
50 |
8 |
40 |
18 |
90 |
18.11± 0.16 |
90.19± 0.11 |
100.61±0.19 |
100.46 ±0.17 |
||||||||||
|
100% |
10 |
50 |
10 |
50 |
20 |
100 |
20.15± 0.19 |
100.29± 0.13 |
100.68 ± 0.22 |
100.29 ± 0.15 |
||||||||||
|
120% |
10 |
50 |
12 |
60 |
22 |
120 |
22.17± 0.13 |
120.47± 0.39 |
100.77 ± 0.15 |
100.78 ± 0.13 |
||||||||||
Table 3
Robustness and ruggedness data into that change in instrument and change in
(±0.2nm)wavelength of both drug.
|
Condition |
Conc. |
Different Instrument |
λmax (± 0.2nm) |
||
|
UV-2450 |
UV-1800 |
312.80nm |
313.20nm |
||
|
Nifedipine Mean(n=3)±%RSD |
5 |
0.039± 0.71 |
0.038± 0.33 |
0.038± 0.37 |
0.039±0.45 |
|
10 |
0.117± 0.32 |
0.118± 0.43 |
0.116± 0.32 |
0.117± 0.51 |
|
|
|
15 |
0.191± 0.41 |
0.193± 0.29 |
0.191± 0.42 |
0.192± 0.75 |
|
|
UV-2450 |
UV-1800 |
275.20nm |
275.60nm |
|
|
Metoprolol Succinate
Mean(n=3)±%RSD |
25 |
0.159± 0.41 |
0.158± 0.59 |
0.157± 0.22 |
0.160± 0.65 |
|
50 |
0.272± 0.39 |
0.273± 0.38 |
0.271± 0.38 |
0.274± 0.22 |
|
|
|
75 |
0.388± 0.52 |
0.389± 0.25 |
0.387± 0.47 |
0.389± 0.17 |
Table 4
LOD&LOQ data for Nifedipine and Metoprolol Succinate.
|
Drugs |
LOD(µg/ml) |
LOQ(µg/ml) |
|||
|
Nifedipine |
0.038 |
0.066 |
||
|
Metoprolol Succinate |
0.115 |
0.200 |
||
Table 5
Result of all validation and development parameters for this proposed method
for Nifedipine and Metoprolol
Succinate.
|
SR. NO. |
PARAMETER |
NIFEDIPINE |
METOPROLOL SUCCINATE |
|||
|
1 |
Linearity(µg/ml)(n=6) |
5-25 |
25-125 |
|||
|
2 |
Regression
equation |
y=0.0742x-0.0361 |
y=0.1094x+0.0498 |
|||
|
3 |
Correlation coefficient(r) |
0.9998 |
0.9991 |
|||
|
4 |
Accuracy
(%Recovery) |
100.68 |
100.33 |
|||
|
5 |
LOD (µg/ml)
(n=10) |
0.066 |
0.20 |
|||
|
6 |
LOQ(µg/ml) (n=10) |
0.030 |
0.64 |
|||
|
7 |
Precision Intra-day(%RSD)(n=3) Inter-day (%RSD)(n=3) |
0.46-0.64 0.40-0.71 |
0.40-0.65 0.22-0.75 |
|||
|
8 |
Robustness (%RSD) |
0.29-0.75 |
0.17-0.59 |
|||
5. CONCLUSION:
A novel, simple, rapid and
sensitive method is proposed for the analysis of two binary mixtures with
overlapping spectra. The method involves the generation of absorbance spectra
followed by measurement of the absorbance. The proposed method does not require
any sophisticated mathematical treatment for the absorption data, and it
exhibits several advantages over other spectrophotometric methods for
resolution of binary mixtures. The applicability of the developed method was
evaluated through the determination of drug combinations in several
laboratory-prepared mixtures with good accuracy and precision. Therefore, the
presented methodology is adequate for the routine quality control analysis of
these fixed-dose combinations.
6. CONFLICT OF INTEREST:
The authors confirm that this article content has no
conflict of interest.
7. REFERENCES:
1.
The European
Pharmacopoeia, 7th Edn; Published by the
European Directorate for the Quality of Medicines & Health Care, Vol. II,
2011, pp. 2495-2496.
2.
Martindale,
Royal Pharmaceutical Society of Great Britain, 34th Edn, The Pharmaceutical Press,London,2005,
pp. 966.
3.
Lippincott
Williams and Wilkins, Foye’s Principles of Medicinal
Chemistry, 5thEdn, 351-west Camden street,
2007, pp. 552.
4.
Brunton L,
Parker K and Buxton L, Goodman and Gillman’s Manual of Pharmacology and Therapeutics,
3rd Edn; the McGraw – Hill Companies
Publication, New York, 2007, pp. 856.
5.
Remington,
The Science & Practice of Pharmacy,21stEdn,
Vol. II, pp. 1366.
6.
Lippincott’s
Illustrated Reviews, Lippincott Williams & Wilkins, Pharmacology, 5th Edn, pp. 236.
7.
Applied
Pharmaceutical Science, The Merck Index: An Encyclopedia of Chemicals, Drugs
& Biological, Merck Research Laboratories, Merck and Co. Inc., 2011, pp.
112-115.
8.
Brunton L,
Parker K and Buxton L, Goodman and Gillman’s manual of pharmacology and
therapeutics, 3rd Edn; the McGraw – Hill Companies
Publication, New York, 2008, pp.178.
Received on 28.01.2015 Accepted on 26.02.2015
© Asian Pharma
Press All Right Reserved
Asian J. Pharm.
Tech. 2015; Vol. 5: Issue 1, Pg
13-16
DOI: 10.5958/2231-5713.2015.00003.3